Artiva Biotherapeutics, Inc. (ARTV)

Price, with every insider trade on it

Closing prices, 12 months · point at a dot for who traded, or at the line for the close

6.94 on 9 Oct 2026

21 buys13 sales at will7 planned sales

Fiscal year 2025, ended 31 Dec 2025, as filed

Revenue

$0.00

Net income

$83.87M

Free cash flow

$79.34M

Return on equity

-76.3%

Return on capital

-64.5%

Fiscal years, as filed with the SEC · point at a year for the detail

RevenueNet incomeLoss

From Form 4, most recent first

Date	Insider	Type	Value	Of own stake
6 Oct 2026	Aslan Fred Chief Executive Officer	Sold on a plan	$168.88K	1.5%
5 Oct 2026	Aslan Fred Chief Executive Officer	Sold at will	$421.83K	3.8%
5 Oct 2026	Horan Christopher Chief Tech Operations Officer	Sold at will	$70.70K	3.2%
5 Oct 2026	Bush Jennifer COO, CLO, Compliance Officer	Sold at will	$57.23K	2.2%
5 Oct 2026	Banerjee Subhashis Chief Medical Officer	Sold at will	$7.51K	0.6%
8 Sep 2026	Aslan Fred Chief Executive Officer	Sold on a plan	$255.75K	1.6%

30out of 100

Profitability 0

Financial strength 59

Growth 0

Insiders 77

Strongest on insiders (77), weakest on growth (0). A score of the business, not of the price.

Last 12 months

Only here

Bought

$109.12M

21 buys, 2 buyers

Sold

$2.67M

20 sales

Planned sales

35%

under a 10b5-1 plan